|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
5
|
Ciprofloxacin
|
Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft
|
1797513
|
440276
|
Ciprofloxacin & Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft
|
## Chronograph ##

## Basic demographioc table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
36
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
196
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
23
|
64
|
Sex
|
gender = FEMALE
|
624
|
62
|
Sex
|
gender = FEMALE
|
106
|
54
|
Sex
|
gender = FEMALE
|
603
|
60
|
|
|
gender = MALE
|
13
|
36
|
|
gender = MALE
|
376
|
38
|
|
gender = MALE
|
90
|
46
|
|
gender = MALE
|
397
|
40
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
0
|
0
|
|
(20,30]
|
7
|
1
|
|
(20,30]
|
0
|
0
|
|
(20,30]
|
6
|
1
|
|
|
(30,40]
|
0
|
0
|
|
(30,40]
|
22
|
2
|
|
(30,40]
|
3
|
2
|
|
(30,40]
|
17
|
2
|
|
|
(40,50]
|
3
|
8
|
|
(40,50]
|
43
|
4
|
|
(40,50]
|
9
|
5
|
|
(40,50]
|
34
|
3
|
|
|
(50,60]
|
2
|
6
|
|
(50,60]
|
74
|
7
|
|
(50,60]
|
8
|
4
|
|
(50,60]
|
65
|
6
|
|
|
(60,70]
|
8
|
22
|
|
(60,70]
|
242
|
24
|
|
(60,70]
|
43
|
22
|
|
(60,70]
|
233
|
23
|
|
|
(70,80]
|
15
|
42
|
|
(70,80]
|
319
|
32
|
|
(70,80]
|
63
|
32
|
|
(70,80]
|
367
|
37
|
|
|
(80,90]
|
5
|
14
|
|
(80,90]
|
231
|
23
|
|
(80,90]
|
53
|
27
|
|
(80,90]
|
229
|
23
|
|
|
(90,110]
|
3
|
8
|
|
(90,110]
|
62
|
6
|
|
(90,110]
|
17
|
9
|
|
(90,110]
|
49
|
5
|
|
|
Median
|
72.5
|
IQR=(66, 80)
|
|
Median
|
74
|
IQR=(67, 82)
|
|
Median
|
76
|
IQR=(68, 84)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 36)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 36)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
8.3
|
2.1
|
-0.28
|
|
25 - 29
|
0
|
0.7
|
0.12
|
Visual system disorder
|
44.4
|
34.8
|
-0.20
|
|
30 - 34
|
0
|
0.9
|
0.13
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0
|
1.2
|
0.16
|
Atrial fibrillation
|
52.8
|
30.0
|
-0.48
|
|
40 - 44
|
5.6
|
0.8
|
-0.27
|
Cerebrovascular disease
|
22.2
|
10.9
|
-0.31
|
|
45 - 49
|
2.8
|
2.8
|
0.00
|
Coronary arteriosclerosis
|
58.3
|
32.6
|
-0.53
|
|
50 - 54
|
0
|
3.6
|
0.27
|
Heart disease
|
91.7
|
59.9
|
-0.80
|
|
55 - 59
|
5.6
|
3.8
|
-0.08
|
Heart failure
|
50.0
|
27.3
|
-0.48
|
|
60 - 64
|
0
|
5.2
|
0.33
|
Ischemic heart disease
|
30.6
|
15.7
|
-0.36
|
|
65 - 69
|
22.2
|
16.4
|
-0.15
|
Peripheral vascular disease
|
58.3
|
30.1
|
-0.59
|
|
70 - 74
|
22.2
|
16.7
|
-0.14
|
Pulmonary embolism
|
2.8
|
4.6
|
0.10
|
|
75 - 79
|
11.1
|
15.6
|
0.13
|
Venous thrombosis
|
16.7
|
6.9
|
-0.31
|
|
80 - 84
|
13.9
|
15.2
|
0.04
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
8.3
|
9.0
|
0.02
|
Hematologic neoplasm
|
25.0
|
8.7
|
-0.45
|
|
90 - 94
|
8.3
|
5.0
|
-0.13
|
Malignant lymphoma
|
11.1
|
3.6
|
-0.29
|
|
95 - 99
|
0
|
1.9
|
0.20
|
Malignant neoplasm of anorectum
|
2.8
|
1.5
|
-0.09
|
|
100 - 104
|
0
|
1.2
|
0.16
|
Malignant neoplastic disease
|
55.6
|
26.1
|
-0.63
|
|
Gender: female
|
63.9
|
62.4
|
-0.03
|
Malignant tumor of breast
|
5.6
|
2.7
|
-0.14
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
11.1
|
3.2
|
-0.31
|
|
Acute respiratory disease
|
52.8
|
24.0
|
-0.62
|
Malignant tumor of lung
|
13.9
|
3.0
|
-0.40
|
|
Attention deficit hyperactivity disorder
|
0
|
0.9
|
0.13
|
Malignant tumor of urinary bladder
|
5.6
|
3.0
|
-0.13
|
|
Chronic liver disease
|
16.7
|
3.8
|
-0.43
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
33.3
|
11.9
|
-0.53
|
Agents acting on the renin-angiotensin system
|
75.0
|
69.3
|
-0.13
|
|
Crohn’s disease
|
2.8
|
1.1
|
-0.12
|
Antibacterials for systemic use
|
58.3
|
48.8
|
-0.19
|
|
Dementia
|
8.3
|
13.1
|
0.15
|
Antidepressants
|
77.8
|
61.7
|
-0.36
|
|
Depressive disorder
|
8.3
|
12.4
|
0.13
|
Antiepileptics
|
38.9
|
38.6
|
-0.01
|
|
Diabetes mellitus
|
86.1
|
53.8
|
-0.75
|
Antiinflammatory and antirheumatic products
|
47.2
|
36.1
|
-0.23
|
|
Gastroesophageal reflux disease
|
13.9
|
16.2
|
0.06
|
Antineoplastic agents
|
16.7
|
11.3
|
-0.16
|
|
Gastrointestinal hemorrhage
|
19.4
|
6.7
|
-0.39
|
Antipsoriatics
|
0
|
1.0
|
0.14
|
|
Human immunodeficiency virus infection
|
0
|
0.4
|
0.09
|
Antithrombotic agents
|
66.7
|
49.3
|
-0.36
|
|
Hyperlipidemia
|
33.3
|
25.3
|
-0.18
|
Beta blocking agents
|
69.4
|
62.8
|
-0.14
|
|
Hypertensive disorder
|
11.1
|
5.0
|
-0.23
|
Calcium channel blockers
|
69.4
|
54.3
|
-0.32
|
|
Lesion of liver
|
19.4
|
4.4
|
-0.48
|
Diuretics
|
66.7
|
70.1
|
0.07
|
|
Obesity
|
5.6
|
7.6
|
0.08
|
Drugs for acid related disorders
|
44.4
|
50.4
|
0.12
|
|
Osteoarthritis
|
58.3
|
38.1
|
-0.41
|
Drugs for obstructive airway diseases
|
38.9
|
38.8
|
0.00
|
|
Pneumonia
|
13.9
|
5.7
|
-0.28
|
Drugs used in diabetes
|
44.4
|
53.5
|
0.18
|
|
Psoriasis
|
0
|
1.1
|
0.15
|
Immunosuppressants
|
5.6
|
4.1
|
-0.07
|
|
Renal impairment
|
75.0
|
25.4
|
-1.14
|
Lipid modifying agents
|
80.6
|
71.5
|
-0.21
|
|
Rheumatoid arthritis
|
11.1
|
7.0
|
-0.14
|
Opioids
|
47.2
|
33.1
|
-0.29
|
|
Schizophrenia
|
16.7
|
7.7
|
-0.28
|
Psycholeptics
|
63.9
|
54.6
|
-0.19
|
|
Ulcerative colitis
|
0
|
0.4
|
0.09
|
Psychostimulants, agents used for adhd and nootropics
|
19.4
|
15.5
|
-0.10
|
|
Urinary tract infectious disease
|
52.8
|
22.3
|
-0.66
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 196)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 196)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
4.6
|
1.4
|
-0.19
|
|
25 - 29
|
0
|
0.5
|
0.10
|
Visual system disorder
|
42.9
|
35.0
|
-0.16
|
|
30 - 34
|
0.5
|
0.9
|
0.05
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
0.9
|
-0.01
|
Atrial fibrillation
|
52.6
|
23.3
|
-0.63
|
|
40 - 44
|
2.6
|
0.5
|
-0.17
|
Cerebrovascular disease
|
15.3
|
8.8
|
-0.20
|
|
45 - 49
|
2.0
|
2.3
|
0.02
|
Coronary arteriosclerosis
|
49.5
|
28.2
|
-0.45
|
|
50 - 54
|
1.0
|
2.6
|
0.12
|
Heart disease
|
84.7
|
55.5
|
-0.67
|
|
55 - 59
|
2.6
|
3.9
|
0.08
|
Heart failure
|
49.5
|
24.0
|
-0.55
|
|
60 - 64
|
3.6
|
3.4
|
-0.01
|
Ischemic heart disease
|
25.5
|
12.6
|
-0.33
|
|
65 - 69
|
14.3
|
16.5
|
0.06
|
Peripheral vascular disease
|
43.4
|
24.3
|
-0.41
|
|
70 - 74
|
16.8
|
19.9
|
0.08
|
Pulmonary embolism
|
6.6
|
1.7
|
-0.25
|
|
75 - 79
|
13.8
|
17.2
|
0.09
|
Venous thrombosis
|
16.8
|
6.3
|
-0.33
|
|
80 - 84
|
16.8
|
15.7
|
-0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
13.8
|
9.4
|
-0.14
|
Hematologic neoplasm
|
18.4
|
8.3
|
-0.30
|
|
90 - 94
|
4.1
|
3.5
|
-0.03
|
Malignant lymphoma
|
7.7
|
4.5
|
-0.13
|
|
95 - 99
|
6.1
|
1.7
|
-0.23
|
Malignant neoplasm of anorectum
|
2.6
|
1.4
|
-0.08
|
|
100 - 104
|
1.0
|
1.1
|
0.01
|
Malignant neoplastic disease
|
49.0
|
26.0
|
-0.49
|
|
Gender: female
|
54.1
|
60.3
|
0.13
|
Malignant tumor of breast
|
6.6
|
3.8
|
-0.13
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
8.2
|
3.2
|
-0.22
|
|
Acute respiratory disease
|
38.8
|
20.7
|
-0.40
|
Malignant tumor of lung
|
4.1
|
2.6
|
-0.08
|
|
Attention deficit hyperactivity disorder
|
1.0
|
0.3
|
-0.09
|
Malignant tumor of urinary bladder
|
3.1
|
2.5
|
-0.03
|
|
Chronic liver disease
|
7.7
|
2.8
|
-0.22
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
21.4
|
8.1
|
-0.38
|
Agents acting on the renin-angiotensin system
|
45.4
|
0
|
-1.29
|
|
Crohn’s disease
|
1.5
|
1.2
|
-0.03
|
Antibacterials for systemic use
|
39.3
|
0
|
-1.14
|
|
Dementia
|
27.0
|
8.3
|
-0.51
|
Antidepressants
|
42.9
|
0
|
-1.22
|
|
Depressive disorder
|
10.2
|
9.0
|
-0.04
|
Antiepileptics
|
24.0
|
0
|
-0.79
|
|
Diabetes mellitus
|
77.6
|
48.3
|
-0.64
|
Antiinflammatory and antirheumatic products
|
21.9
|
0
|
-0.75
|
|
Gastroesophageal reflux disease
|
15.8
|
14.1
|
-0.05
|
Antineoplastic agents
|
13.3
|
0
|
-0.55
|
|
Gastrointestinal hemorrhage
|
9.2
|
6.9
|
-0.08
|
Antipsoriatics
|
1.0
|
0
|
-0.14
|
|
Human immunodeficiency virus infection
|
1.5
|
0.1
|
-0.16
|
Antithrombotic agents
|
44.4
|
0
|
-1.26
|
|
Hyperlipidemia
|
35.7
|
22.1
|
-0.30
|
Beta blocking agents
|
39.8
|
0
|
-1.15
|
|
Hypertensive disorder
|
11.2
|
4.8
|
-0.24
|
Calcium channel blockers
|
35.7
|
0
|
-1.05
|
|
Lesion of liver
|
7.7
|
2.3
|
-0.25
|
Diuretics
|
43.9
|
0
|
-1.25
|
|
Obesity
|
10.2
|
4.8
|
-0.21
|
Drugs for acid related disorders
|
32.7
|
0
|
-0.98
|
|
Osteoarthritis
|
59.2
|
33.6
|
-0.53
|
Drugs for obstructive airway diseases
|
25.5
|
0
|
-0.83
|
|
Pneumonia
|
10.2
|
4.8
|
-0.21
|
Drugs used in diabetes
|
38.3
|
0
|
-1.11
|
|
Psoriasis
|
3.1
|
1.2
|
-0.13
|
Immunosuppressants
|
2.6
|
0
|
-0.23
|
|
Renal impairment
|
51.0
|
20.7
|
-0.67
|
Lipid modifying agents
|
41.8
|
0
|
-1.20
|
|
Rheumatoid arthritis
|
5.6
|
6.3
|
0.03
|
Opioids
|
32.1
|
0
|
-0.97
|
|
Schizophrenia
|
9.2
|
3.8
|
-0.22
|
Psycholeptics
|
38.8
|
0
|
-1.13
|
|
Ulcerative colitis
|
1.5
|
0.6
|
-0.09
|
Psychostimulants, agents used for adhd and nootropics
|
9.7
|
0
|
-0.46
|
|
Urinary tract infectious disease
|
38.8
|
18.7
|
-0.45
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 196)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 196)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
4.6
|
1.4
|
-0.19
|
|
25 - 29
|
0
|
0.5
|
0.10
|
Visual system disorder
|
42.9
|
35.0
|
-0.16
|
|
30 - 34
|
0.5
|
0.9
|
0.05
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.0
|
0.9
|
-0.01
|
Atrial fibrillation
|
52.6
|
23.3
|
-0.63
|
|
40 - 44
|
2.6
|
0.5
|
-0.17
|
Cerebrovascular disease
|
15.3
|
8.8
|
-0.20
|
|
45 - 49
|
2.0
|
2.3
|
0.02
|
Coronary arteriosclerosis
|
49.5
|
28.2
|
-0.45
|
|
50 - 54
|
1.0
|
2.6
|
0.12
|
Heart disease
|
84.7
|
55.5
|
-0.67
|
|
55 - 59
|
2.6
|
3.9
|
0.08
|
Heart failure
|
49.5
|
24.0
|
-0.55
|
|
60 - 64
|
3.6
|
3.4
|
-0.01
|
Ischemic heart disease
|
25.5
|
12.6
|
-0.33
|
|
65 - 69
|
14.3
|
16.5
|
0.06
|
Peripheral vascular disease
|
43.4
|
24.3
|
-0.41
|
|
70 - 74
|
16.8
|
19.9
|
0.08
|
Pulmonary embolism
|
6.6
|
1.7
|
-0.25
|
|
75 - 79
|
13.8
|
17.2
|
0.09
|
Venous thrombosis
|
16.8
|
6.3
|
-0.33
|
|
80 - 84
|
16.8
|
15.7
|
-0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
13.8
|
9.4
|
-0.14
|
Hematologic neoplasm
|
18.4
|
8.3
|
-0.30
|
|
90 - 94
|
4.1
|
3.5
|
-0.03
|
Malignant lymphoma
|
7.7
|
4.5
|
-0.13
|
|
95 - 99
|
6.1
|
1.7
|
-0.23
|
Malignant neoplasm of anorectum
|
2.6
|
1.4
|
-0.08
|
|
100 - 104
|
1.0
|
1.1
|
0.01
|
Malignant neoplastic disease
|
49.0
|
26.0
|
-0.49
|
|
Gender: female
|
54.1
|
60.3
|
0.13
|
Malignant tumor of breast
|
6.6
|
3.8
|
-0.13
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
8.2
|
3.2
|
-0.22
|
|
Acute respiratory disease
|
38.8
|
20.7
|
-0.40
|
Malignant tumor of lung
|
4.1
|
2.6
|
-0.08
|
|
Attention deficit hyperactivity disorder
|
1.0
|
0.3
|
-0.09
|
Malignant tumor of urinary bladder
|
3.1
|
2.5
|
-0.03
|
|
Chronic liver disease
|
7.7
|
2.8
|
-0.22
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
21.4
|
8.1
|
-0.38
|
Agents acting on the renin-angiotensin system
|
45.4
|
0
|
-1.29
|
|
Crohn’s disease
|
1.5
|
1.2
|
-0.03
|
Antibacterials for systemic use
|
39.3
|
0
|
-1.14
|
|
Dementia
|
27.0
|
8.3
|
-0.51
|
Antidepressants
|
42.9
|
0
|
-1.22
|
|
Depressive disorder
|
10.2
|
9.0
|
-0.04
|
Antiepileptics
|
24.0
|
0
|
-0.79
|
|
Diabetes mellitus
|
77.6
|
48.3
|
-0.64
|
Antiinflammatory and antirheumatic products
|
21.9
|
0
|
-0.75
|
|
Gastroesophageal reflux disease
|
15.8
|
14.1
|
-0.05
|
Antineoplastic agents
|
13.3
|
0
|
-0.55
|
|
Gastrointestinal hemorrhage
|
9.2
|
6.9
|
-0.08
|
Antipsoriatics
|
1.0
|
0
|
-0.14
|
|
Human immunodeficiency virus infection
|
1.5
|
0.1
|
-0.16
|
Antithrombotic agents
|
44.4
|
0
|
-1.26
|
|
Hyperlipidemia
|
35.7
|
22.1
|
-0.30
|
Beta blocking agents
|
39.8
|
0
|
-1.15
|
|
Hypertensive disorder
|
11.2
|
4.8
|
-0.24
|
Calcium channel blockers
|
35.7
|
0
|
-1.05
|
|
Lesion of liver
|
7.7
|
2.3
|
-0.25
|
Diuretics
|
43.9
|
0
|
-1.25
|
|
Obesity
|
10.2
|
4.8
|
-0.21
|
Drugs for acid related disorders
|
32.7
|
0
|
-0.98
|
|
Osteoarthritis
|
59.2
|
33.6
|
-0.53
|
Drugs for obstructive airway diseases
|
25.5
|
0
|
-0.83
|
|
Pneumonia
|
10.2
|
4.8
|
-0.21
|
Drugs used in diabetes
|
38.3
|
0
|
-1.11
|
|
Psoriasis
|
3.1
|
1.2
|
-0.13
|
Immunosuppressants
|
2.6
|
0
|
-0.23
|
|
Renal impairment
|
51.0
|
20.7
|
-0.67
|
Lipid modifying agents
|
41.8
|
0
|
-1.20
|
|
Rheumatoid arthritis
|
5.6
|
6.3
|
0.03
|
Opioids
|
32.1
|
0
|
-0.97
|
|
Schizophrenia
|
9.2
|
3.8
|
-0.22
|
Psycholeptics
|
38.8
|
0
|
-1.13
|
|
Ulcerative colitis
|
1.5
|
0.6
|
-0.09
|
Psychostimulants, agents used for adhd and nootropics
|
9.7
|
0
|
-0.46
|
|
Urinary tract infectious disease
|
38.8
|
18.7
|
-0.45
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
50
|
|
antithrombotic agents
|
48
|
|
antihistamines for systemic use
|
36
|
|
cardiovascular system
|
36
|
|
alimentary tract and metabolism
|
35
|
|
nervous system
|
35
|
|
stomatological preparations
|
34
|
|
respiratory system
|
33
|
|
all other therapeutic products
|
32
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
30
|
|
lipid modifying agents
|
29
|
|
lipid modifying agents, plain
|
29
|
|
psychoanaleptics
|
29
|
|
antidepressants
|
28
|
|
antiepileptics
|
28
|
|
blood and blood forming organs
|
28
|
|
agents acting on the renin-angiotensin system
|
27
|
|
analgesics
|
27
|
|
hmg coa reductase inhibitors
|
27
|
|
musculo-skeletal system
|
26
|
|
antiinfectives for systemic use
|
25
|
|
calcium channel blockers
|
25
|
|
dermatologicals
|
25
|
|
other analgesics and antipyretics
|
25
|
|
sensory organs
|
25
|
|
cond_180_days
|
n_180_days
|
|
pain
|
35
|
|
pain finding at anatomical site
|
35
|
|
heart disease
|
33
|
|
kidney disease
|
32
|
|
arthropathy
|
31
|
|
diabetes mellitus
|
31
|
|
measurement finding outside reference range
|
31
|
|
pain of truncal structure
|
31
|
|
vascular disorder
|
31
|
|
inflammation of specific body organs
|
30
|
|
inflammation of specific body systems
|
30
|
|
soft tissue lesion
|
30
|
|
abnormal blood cell count
|
29
|
|
type 2 diabetes mellitus
|
29
|
|
measurement finding below reference range
|
28
|
|
anemia
|
27
|
|
cytopenia
|
27
|
|
erythropenia
|
27
|
|
hemoglobin level outside reference range
|
27
|
|
hemoglobin low
|
27
|
|
rbc count abnormal
|
27
|
|
rbc count low
|
27
|
|
renal impairment
|
27
|
|
structural disorder of heart
|
25
|
|
cardiac arrhythmia
|
24
|